Shares of Vertex (VRTX -0.76%) skyrocketed today, on very exciting news coming from a phase 2 trial of one of the company's cystic fibrosis drugs. Is Vertex the next big biotech that investors need to be a part of? In this video, Motley Fool health-care analyst David Williamson talks about the phase 2 results, and why investors should stand up and pay attention, and tells us where the company could go in 2013.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.